BCA
ATXI

Berman Capital Advisors’s Avenue Therapeutics, Inc. Common Stock ATXI Stock Holding History

Berman Capital Advisors’s Portfolio ATXI Stock Details ATXI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-1
Closed -$3K – 2080
2021
Q1 		$3K Hold
1
– – ﹤0.01% 1458
2020
Q4 		$3K Buy
+1
New +$5.24K ﹤0.01% 1344

Other funds holding ATXI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BRWA
B. Riley Wealth Advisors Boca Raton, Florida $1.87B AUM 37.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EL
EMFO LLC Weston, Florida $112M AUM 18.79% 1-Year Est. Return
ASN
Advisory Services Network Atlanta, Georgia $7.52B AUM 29.01% 1-Year Est. Return
E
Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Berman Capital Advisors's ATXI Position: Q2 2021 in Review

Berman Capital Advisors sold out of Avenue Therapeutics, Inc. Common Stock (ATXI) in Q2 2021, closing a stake of 1 share — an estimated $3K sold.

Berman Capital Advisors first reported a position in ATXI in Q4 2020 and held it in 2 quarters. The position peaked at $3K in Q1 2021. 24 funds tracked by Wall St. Rank hold ATXI as of Q2 2021.

  • Berman Capital Advisors reported no remaining Avenue Therapeutics, Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
  • Berman Capital Advisors sold 1 Avenue Therapeutics, Inc. Common Stock share in Q2 2021, an estimated $3K.
  • Berman Capital Advisors first reported a position in Avenue Therapeutics, Inc. Common Stock in Q4 2020 and held it in 2 quarters.
  • Berman Capital Advisors's Avenue Therapeutics, Inc. Common Stock position peaked at $3K in Q1 2021.
  • 24 funds tracked by Wall St. Rank held Avenue Therapeutics, Inc. Common Stock as of Q2 2021.

Based on Berman Capital Advisors's 13F filing for Q2 2021, filed 11 Aug 2021.